A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer

Carlos L. Arteaga, Anne O'Neill, Stacy L. Moulder, Michael Pins, Joseph A. Sparano, George W. Sledge, Nancy E. Davidson

Research output: Contribution to journalArticlepeer-review

65 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences